Pathios Therapeutics
1 known investors
Pathios Therapeutics develops GPR65 inhibitor therapeutics for cancer immunotherapy. The company is advancing orally-bioavailable small molecule treatments designed to restore anti-tumor immune cell function in solid cancers by targeting acid-sensing pathways in the tumor microenvironment.